| GERON CORP. (DEL.) DL-001 |
| USA |
| Gesundheit |
| US3741631036 / 902213 |
| GON (Frankfurt) / GERN (NASDAQ) |
| FRA:GON, ETR:GON, GON:GR, NASDAQ:GERN |
| - |
| https://www.geron.com/ |
|
Geron Corporation is a commercial-stage biopharmaceutical company focused on blood cancers and myeloid hematologic malignancies through telomerase inhibition. The company's primary product is RYTELO (imetelstat), a first-in-class telomerase inhibitor..
>Volltext.. |
| 959.96 Mio. EUR |
| 868.89 Mio. EUR |
| 157.47 Mio. EUR |
| -45.07 Mio. EUR |
| -73.46 Mio. EUR |
| -0.11 EUR |
| 215.44 Mio. EUR |
| 68.03 Mio. EUR |
| -95.09 Mio. EUR |
| 3.23 |
| 110.5% |
| 56.69% |
| - |
| - |
| - |
| - |
| GERON |
| 08.04.26 |
|